FDA Grants Orphan Drug Designation for VAL001
Respiratorius AB has been granted Orphan Drug Designation by US Food and Drug Administration (FDA) for valproic acid for the treatment of Diffuse Large B-cell Lymphoma.VAL001 is a combination of a HDAC inhibitor (valproic acid) and a steroid (prednisone) and referred to as a pretreatment before chemotherapy (R-CHOP), for the treatment of diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, and the most common type of non-Hodgkin lymphoma, and constitute 30% of patients diagnosed with this type of cancer. Annually diagnosed approximately 20 000 people in the US